vialroom

#retatrutide 2025-04-24

Thursday35 messages7 participantstimes are UTC
Highlights from this day
  • gip_glp_gil — there is no long term safety data, phase 2 and an ongoing phase 3 programme is what exists 19:41
  • gip_glp_gil — VendorInvestigate came back 99 on one lot and 98.6 on the next from the same CPC, both fine 19:43
  • week_zero — the glucagon arm is the mechanistic story for extra energy expenditure and its still a story to me, i could be wrong 19:50
  • reta_resting_hr — anyone reconstituting 5 vials to 10 so the steps come out smaller 19:55
  • customs_owl — buying this is a completely different risk conversation from the licensed compounds and that gets said too rarely 21:49
WZ

no idea whether the heart rate settles for everyone, mine did and one log isnt data

why does everyone insist on smaller steps here than on the other two

stepping in 1.7 increments instead of doubling is the only thing i would change if i started again

triple agonist yeah

GG

there is no long term safety data, phase 2 and an ongoing phase 3 programme is what exists

🤝12💀7

VendorInvestigate came back 99 on one lot and 98.6 on the next from the same CPC, both fine

PT

i was wrong to call the heart rate a non issue last year, enough people logged it that i changed my mind

CC

my resting rate went up 7 bpm in the first month and came back most of the way by month 4, thats one data point

[edited]

how do people square the research use only framing with logging their own use

i said 5 months ago that my heart rate had settled and it has stayed settled since

WZ

the glucagon arm is the mechanistic story for extra energy expenditure and its still a story to me, i could be wrong

unrelated but TRIUMPH is the phase 3 programme, thats the name to search rather than the molecule

energy expenditure isnt something i could feel, though my sleep tracker disagreed with me, anyway

logging rhr daily

DO

blood pressure stayed flat for me while heart rate moved, which i didnt expect

DO

does the glucagon arm explain the heart rate or is that unrelated

DO

cant feel it honestly

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.
💀3🔥107
RR

low and slow here means smaller steps than i ever used on tirzepatide, thats the received wisdom

CO

whats a sensible starting point, im seeing everything from 0.5 to 2

DO

genuine question is there any long term safety data at all or is it phase 2 and hope

im at 2.5 and the appetite effect is stronger than i expected, normal

CO

the half life supports weekly dosing and thats what ive done from the start

slightly off topic but triple agonist meaning GLP-1, GIP and glucagon, have i got that right

did the phase 2 result actually come in higher than the tirzepatide numbers

buying this is a completely different risk conversation from the licensed compounds and that gets said too rarely

whats the half life like, is it weekly the same way

GG

appetite suppression at 2.5 was stronger than my tirzepatide experience at a comparable point